Peroxitech Inc., announced the successful completion of a $25M Series A financing round that will help to advance its lead candidate, PIP-2, for the treatment of acute lung injury (ALI) into clinical development. The company was launched in 2016 through the UPstart program at PCI and was co-founded by Aron Fisher, MD, Director, Institute for Environmental Medicine and Sheldon Feinstein, PhD, Senior Research Director, Institute for Environmental Medicine. Peroxitech is also evaluating PIP-2 for several other high unmet need areas where modulation of oxidative injury signaling pathways may allow better treatment options for patients suffering from various types of inflammatory syndromes.